Portland, ORNCT07590934Now EnrollingIRB Ready

Metastatic Prostate Cancer Clinical Trial in Portland, OR

Access cutting-edge metastatic prostate cancer treatment through this clinical trial at a research site in Portland. Study-provided care at no cost to qualified participants.

Sponsored by AstraZeneca

Quick Self-Assessment

See if you qualify for this Portland location

Preparing your pre-screening questions…

Expert Care in Portland

Access metastatic prostate cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related metastatic prostate cancer treatment provided free

Apply for This Portland Location

Check if you qualify for this metastatic prostate cancer clinical trial in Portland, OR

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Portland

    Convenient for OR residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Portland site if eligible
  4. 4Begin participation

About This Metastatic Prostate Cancer Study in Portland

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer.

Sponsor: AstraZeneca

Who Can Participate

Inclusion Criteria

Participants with a diagnosis of histologically confirmed adenocarcinoma of the prostate (no small cell, neuroendocrine, sarcomatoid, spindle or signet cell).
Minimum life expectancy of 3 months or more.
Eastern Cooperative Oncology Group (ECOG) performance status of O or 1 at screening, with no deterioration.
PCWG3 (Prostate Cancer Working Group 3) modified RECIST Version 1.1 evaluable disease.
Must have received at least one novel androgen receptor pathway inhibitor (ARPI), such as enzalutamide or darolutamide or apalutamide or abiraterone acetate.
Must have one or more unresectable metastatic lesions.
Must have had prior orchiectomy and/or ongoing androgen deprivation therapy, and a castrate level of serum testosterone (\<50ng/dL or \<l.7nmol/L).
Progressive metastatic castration-resistant prostate cancer (mCRPC) following the most recent treatment at time of study entry.
Adequate organ and marrow function.
Non sterilised participants who are sexually active with a partner of childbearing potential must use a condom (plus spermicide, if available), must refrain from fathering a child, freezing or donating sperm, and it is recommended for the partner to also use a highly effective contraceptive method. Inclusion Criteria for Sub study 1:
Must have received a single line of ARPI, such as enzalutamide, darolutamide, apalutamide or abiraterone acetate.
PSMA positive mCRPC by computed tomography positron emission tomography, obtained with PSMA ligand defined as at least 1 PSMA positive metastatic lesion with tracer uptake greater than liver, and no PSMA negative lesions. All measurable or intraprostatic lesions must be PSMA positive.
Capable of self-administering oral formulations.

Exclusion Criteria

Any evidence of non adenocarcinomatous forms of prostate cancer (including small cell, spindle cell, signet cell, neuroendocrine, sarcomatous).
Known, unresolved urinary tract obstruction.
Participants with a history of central nervous system metastases.
Symptomatic malignant spinal cord compression or findings indicative of impending cord compression.
Participants with a history of leptomeningeal carcinomatosis.
Previous or concurrent cancer distinct from the cancer under investigation in primary site or histology .
Concurrent serious medical conditions.
Previous history of interstitial lung disease or non-infectious pneumonitis.
Participants with a history or clinical/laboratory features suggestive of myelodysplastic syndrome or acute myeloid leukaemia.
Persistent toxicities caused by previous therapy.
Participants unable to swallow orally administered medications or with gastrointestinal disorders likely to interfere with absorption.
Active infection, including tuberculosis, hepatitis C virus, and hepatitis B virus infection.
Known hypersensitivity to study intervention or any of their excipients. Exclusion Criteria for Sub study 1:
History of uncontrolled seizures or requirement for \>2 antiepileptic drugs.
History of severe brain injury or stroke.
Skeletal metastases demonstrating a superscan appearance on bone scan.
Participants have received prior therapy with AZD9574 or more than 1 prior line of any other Poly-ADP-ribose polymerase inhibitor (PARPi)-based regimen (either as a treatment or as maintenance).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Portland?

Yes, this clinical trial (NCT07590934) has an active research site in Portland, OR that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Metastatic Prostate Cancer Treatment Options in Portland, OR

If you're searching for metastatic prostate cancer treatment options in Portland, OR, this clinical trial (NCT07590934) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Portland research site is actively enrolling participants for this clinical trial. You'll receive care from experienced metastatic prostate cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all metastatic prostate cancer clinical trials near you to find additional studies recruiting in your area.

More Prostate Cancer Trials in Portland, OR

See all prostate cancer clinical trials recruiting in Portland — not just this study.

Browse Prostate Cancer Trials in Portland →

Browse More Trials by Condition

Prostate Cancer TrialsEssential Tremor TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Portland?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Portland, OR